Clinical trials: Oro-cecal Transit Time
Intestinal Obstruction
Effects of Methylnaltrexone in Comparison to Naloxone on Loperamide-induced Delay of the Oro-cecal, Whole-gut and Colon Transit Time.
The purpose of this study is to describe the effects of repeated-dose methylnaltrexone in preventing loperamide-induced delay of whole-gut, oro-cecal and colon transit time and to measure pharmacokinetics of methylnaltrexone and…
- Trial name
- NCT01596764
- Testing
- Loperamide, Colon Transit, Sulfasalazine
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University Medicine Greifswald
Gastric Emptying, Healthy
Effect of Dexmedetomidine on Gastric Emptying and Gastrointestinal Transit
The aim of the study is to determine the effect of dexmedetomidine infusion on gastric emptying and oro-caecal transit time in healthy volunteers, judged by measuring plasma paracetamol concentrations after paracetamol ingestion…
- Trial name
- GADEX (NCT01084473)
- Testing
- Dexmedetomidine, Morphine
- Where
- Finland
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Turku
Small Bowel Disease, Motility Disorder
Study of Oro-cecal Transit Time in Healthy Subjects Using Scintigraphy and Lactulose Hydrogen Breath Test.
Radionuclide scintigraphy is the gold standard technique to interpret OCTT but there is no normative data available for its interpretation in Indian population.
- Conditions
- Small Bowel Disease, Motility Disorder, Irritable Bowel Syndrome
- Trial name
- NCT05004207
- Testing
- 99mTc Scintigraphy
- Where
- India
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Asian Institute of Gastroenterology, India
Small Bowel Bacterial Overgrowth, Gastrointestinal Diseases
Transit Time and Bacterial Overgrowth Using SmartPill Capsule
The primary purpose of this exploratory study is to measure orocecal transit time using the SmartPill ambulant capsule technology and to compare this with the lactulose hydrogen breath test.
- Conditions
- Small Bowel Bacterial Overgrowth, Gastrointestinal Diseases, Stomach Diseases, Digestive System Diseases
- Trial name
- NCT00577772
- Testing
- Xifaxan, SmartPill, Lactulose hydrogen breath test (H_2BT)
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Cystic Fibrosis, Gastrointestinal Dysfunction
Understanding Gut Symptoms in People With Cystic Fibrosis
Although chest infections affect wellbeing and survival in cystic fibrosis (CF), most people with CF also have difficulty digesting food and must take medication for this.
- Trial name
- GRAMPUS-CF SRC (NCT05934656)
- Testing
- Latent class analysis
- Where
- United Kingdom
- Volunteers
- 350 people
- Sponsor
- University of Nottingham
Constipation
Prucalopride in Patients With Chronic Idiopathic Constipation
The purpose of this study is to determine whether prucalopride is safe and effective in the treatment of chronic idiopathic constipation. Hypothesis: Prucalopride given at a dose of 1 mg o.d.
- Trial name
- NCT00575614
- Testing
- prucalopride
- Volunteers
- 87 people
- Sponsor
- Movetis
Oro-cecal Transit Time
Rapid Orocecal Transit Time and Fermentation in IBS.
Orocecal transit time is studied in individuals with irritable bowel syndrome (IBS) of both the constipation-dominant, diarrhea-dominant, and mixed form using the lactulose hydrogen breath test for orocecal transit time through…
- Trial name
- RapidoIBS (NCT03141268)
- Testing
- Lactulose breath test
- Where
- Sweden
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Uppsala University
Intestinal Obstruction
Effects of 500 mg Immediate Release and Extended Release Methylnaltrexone on Loperamide-induced Delay of the Oro-cecal and Whole-gut Transit Time in Healthy Subjects
The purpose of this study is to describe the effects of methylnaltrexone in preventing loperamide-induced delay of the oro-cecal and whole-gut transit time and measure pharmacokinetics of methylnaltrexone after subcutaneous and…
- Trial name
- LOP-MNTX-2009 (NCT01596777)
- Testing
- Loperamide, Methylnaltrexone 12 mg sc., Methylnaltrexone IR capsule
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University Medicine Greifswald
Cystic Fibrosis
Gut Imaging for Function & Transit in CF - GIFT-CF 3
An observational study of patients with cystic fibrosis (CF) starting treatment with Kaftrio (Elexacaftor / Tezacaftor / Ivacaftor) as part of routine clinical care, following EMA licensing (approved end of Aug 2020).
- Trial name
- GIFT-CF3 (NCT04618185)
- Testing
- Magnetic Resonance Imaging (MRI)
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- Nottingham University Hospitals NHS Trust